Samsung Bioepis’ citrate-free, high-concentration Hadlima (adalimumab) biosimilar will be introduced in Canada via partner Organon “later in 2023” after it was approved by Health Canada, adding to the Korean firm’s existing approval and launch of the low-concentration formulation.
The company’s planned 40mg/40ml presentation launch is to further shake up the market for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?